Posted: 11 August 2025
VivaZome Therapeutics has published a major review artcile in Health Nanotechnology, titled “Customised extracellular vesicle therapeutics for neurological conditions.” The paper was authored by Dr Ella Johnston, with co-authors Johannes Weber, Xenia Sango (CEO), Dr Ian Nisbet, and Professor David Haylock (CSO). It was described as providing a comprehensive overview of the design and development of customised extracellular vesicles.
The review explored surface modification approaches that had been employed to improve EV targeting to therapeutic sites – particularly in neurological settings – and examined the loading of therapeutic agents into EVs, such as proteins, nucleic acids, or small-molecule drugs. Challenges associated with effectively delivering these EVs across the blood- brain barrier were also discussed.
Professor David Haylock stated, “This review highlighted the critical and unmet need for treatments across a range of neurological conditions and the emerging role of EV-based therapies in these conditions.” It was noted that Dr Johnston and her co-authors had described methods for loading therapeutic agents into EVs, as well as strategies for surface engineering to improve brain targeting. It was further mentioned that VivaZome had actively advanced programs in both cargo loading and surface modification, and had successfully engineered cell lines to enhance EV activity. This work was noted to align closely with the recent ARC Fellowship awarded to Dr Johnston.
For more information click here.
